Aiosyn, a company that develops AI-powered pathology algorithms for clinical diagnostics and life sciences, was awarded early-phase funding of Eur 250.000 by NWO (Dutch Research Council). This additional funding allows Aiosyn to accelerate its mission: increasing the adoption of artificial intelligence in pathology diagnostics and improving the chances of cancer patients worldwide.
Source: https://www.aiosyn.com/news/take-off-2-early-phase-funding/
Related news items
Digital Health partners around Nijmegen join forces
26 January 2022Health Valley has published a Digital Health Guide to connect Digital Health parties around Nijmegen and beyond.
read more
Thirona closes financing round
2 November 2021Radboudumc spin-off Thirona just closed a financing round with Belgian investment fund HERAN Partners and Borski Fund from the Netherlands.
read more
Aiosyn has been selected for Techleap's Pole Position Program
28 October 2021This program focuses on helping 10 ambitious companies within the medical field to reach the scaleup growth phase.
read more